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Myocardial characterization in pre-dialysis
chronic kidney disease: a study of
prevalence, patterns and outcomes
Anna M. Price1,2 , Manvir K. Hayer1,2, Ravi Vijapurapu3, Saad A. Fyyaz3, William E. Moody1,3, Charles J. Ferro1,2,
Jonathan N. Townend1,3, Richard P. Steeds1,3 and Nicola C. Edwards1,4*
Abstract
Background: Late gadolinium enhancement (LGE) using cardiac magnetic resonance (CMR) characterizes
myocardial disease and predicts an adverse cardiovascular (CV) prognosis. Myocardial abnormalities, are present in
early chronic kidney disease (CKD). To date there are no data defining prevalence, pattern and clinical implications
of LGE-CMR in CKD.
Methods: Patients with pre-dialysis CKD (stage 2–5) attending specialist renal clinics at University Hospital
Birmingham (UK) who underwent gadolinium enhanced CMR (1.5 T) between 2005 and 2017 were included. The
patterns and presence (LGEpos) / absence (LGEneg) of LGE were assessed by two blinded observers. Association
between LGE and CV outcomes were assessed.
Results: In total, 159 patients received gadolinium (male 61%, mean age 55 years, mean left ventricular ejection
fraction 69%, left ventricular hypertrophy 5%) with a median follow up period of 3.8 years [1.04–11.59]. LGEpos was
present in 55 (34%) subjects; the patterns were: right ventricular insertion point n = 28 (51%), mid wall n = 18 (33%),
sub-endocardial n = 5 (9%) and sub-epicardial n = 4 (7%). There were no differences in left ventricular structural or
functional parameters with LGEpos. There were 12 adverse CV outcomes over follow up; 7 of 55 with LGEpos and 5
of 104 LGEneg. LGEpos was not predicted by age, gender, glomerular filtration rate or electrocardiographic
abnormalities.
Conclusions: In a selected cohort of subjects with moderate CKD but low CV risk, LGE was present in
approximately a third of patients. LGE was not associated with adverse CV outcomes. Further studies in high risk
CKD cohorts are required to assess the role of LGE with multiplicative risk factors.
Keywords: Cardiac magnetic resonance, Gadolinium, Chronic kidney disease, Fibrosis
Background
Patterns of late gadolinium enhancement (LGE) identi-
fied by cardiac magnetic resonance (CMR) imaging are
integral to characterizing myocardial disease and are
predictive of adverse cardiovascular (CV) outcome in
both ischaemic and non-ischaemic disease [1, 2] LGE
correlates with expansion of the extracellular matrix of
the myocardium through perivascular and replacement
fibrosis and predicts increased mortality and CV hospi-
talisation independently of other routinely assessed
CMR parameters including left ventricular ejection frac-
tion (LVEF) [1–3]. Furthermore, the absence of mid-wall
fibrosis in non-ischaemic cardiomyopathy has been asso-
ciated with improved reverse LV (left ventricular) re-
modelling following cardiac resynchronisation therapy
and better long-term survival with both severe and mild-
moderate degrees of systolic impairment [1, 2, 4]. Left
ventricular hypertrophy (LVH), dilatation and systolic
impairment constitute “uremic cardiomyopathy” and are
thought to explain the disproportionate rates of heart
failure and sudden death which constitute almost 50% of
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deaths in end-stage kidney disease (ESKD) compared to
only 6.7% from myocardial infarction / ischaemia [5, 6].
Myocardial interstitial fibrosis is present on endomyo-
cardial biopsy in ESKD and on CMR late gadolinium en-
hancement imaging (LGE-CMR) with sub-endocardial
(14%) and mid-wall patterns (14%) in patients without
diagnosed CV disease [7, 8]. Subsequent observational
CMR studies have confirmed that myocardial abnormal-
ities of systolic deformation and interstitial fibrosis are
detectable from the earliest stages of CKD, before devel-
opment of LVH, or a reduction in LVEF, emphasising
the potential importance of myocardial disease in driving
adverse outcomes in this cohort [9]. The significance of
LGE in CKD remains unknown.
Methods
Study design and population
A retrospective study of patients with pre-dialysis CKD
(stages 2–5; estimated glomerular filtration rate (eGFR)
90 to < 15ml/min/1.73m2) undergoing CMR as part of
clinical research studies between 2005 and 2017, see
Additional file 1: Table S1 for details [9, 10]. Patients
provided consent to take part and allow retrospective
follow up. Detailed inclusion / exclusion study criteria
and patient clinical characteristics are outlined in Add-
itional file 1: Table S1. Patients were recruited from
studies investigating the changes in non-ischaemic myo-
cardial structure and function, including fibrosis, in early
CKD. All patients were recruited from specialist renal
clinics at a tertiary unit in Birmingham, UK and were
followed up regularly. Trial exclusion criteria included;
diagnosed coronary/ peripheral artery disease, LVEF <
50%, and diabetes, with the aim of reducing possible
confounding effects of atheromatous disease.
Data collection
Patient demographics, haematological and biochemical
data were obtained from electronic patient records sys-
tem (Clinical Portal©). Renal aetiology was confirmed on
imaging or biopsy studies and eGFR calculated by the
creatinine based Modification of diet in renal disease
(MDRD) equation at baseline [11].
Cardiac magnetic resonance protocol
CMR (1.5 T, MAGNETOM Symphony and Avanto: Sie-
mens, Erlangen, Germany) was performed to assess LV
and right ventricular (RV) volumes, function, and LV
mass using standard breath-hold steady state free pre-
cession sequences. Gadolinium contrast (Magnevist®,
Gadovist®) at a dose 0.15–0.2 mmol/Kg was administered
to subjects with eGFR > 15 ml/min/1.73m2 between
2005 and 2012 and > 30 ml/min/1.73m2 between 2012
and 2017 following a change in Medicines and Health-
care Products Regulatory Agency guidelines. Standard
T1-weighted gradient echo inversion recovery images
were performed at 7–10min after contrast in standard
long axis and short axis stack imaging.
CMR analysis
Offline analysis was performed by experienced operators
(NE, AP) using cvi42® software (version 5.3.4 cvi42, Cir-
cle Vascular Imaging, Canada). Analysis of LV function,
volume and LV mass was performed with delineation of
papillary muscles and trabeculations using thresholding
[12]. LV hypertrophy was defined based on age and gen-
der [13]. The presence and pattern of LGE was assessed
qualitatively and quantitatively by both observers and
defined as LGEpos if present on two or more contiguous
short axis slices or on corresponding long axis images
with appropriate phase swapping. Patterns were defined
as; sub-endocardial, diffuse / mid wall, sub-epicardial
and focal right ventricular insertion point (RVIP) ac-
cording to previous published descriptions [14]. Quanti-
fication of LGE was determined using full width half
max methodology and expressed as the total percentage
of the LV mass, see Fig. 1 [16].
Follow up
Follow-up was defined from the date of CMR to the date
of either the last outpatient clinic episode or the last
known inpatient admission. Right censoring was used
for survival analysis. Adverse events were recorded from
electronic patient records systems. Major adverse CV
clinical outcomes were defined as death from CV dis-
ease, myocardial infarction, stroke, peripheral vascular
disease, or hospital admission with heart failure. Cause
of death was classified according to 1a and 1b on the
death certificate. Total admissions, renal admissions (de-
fined as routine management of CKD such as intraven-
ous iron infusions, access surgery or admissions related
to transplantation) and non-renal admissions were
recorded.
Statistical analysis
Statistical analysis was performed using IBM SPSS© ver-
sion 23 Armonk, New York. Significance was classified
as a p value < 0.05. Continuous parametric variables
were analysed using unpaired t tests (age, eGFR, blood
pressure, body mass index, ventricular volumes and
mass), non-parametric data such as N-terminal pro b-
type natriuretic peptide (NTproBNP) was analysed after
the data was logged. A one-way analysis of variance was
used for continuous parametric variables with more than
two groups. Binary variables such as immunosuppressive
therapy, anti-hypertensive therapy, sex, presence of left
ventricular hypertrophy and statin use were analysed
using Fisher’s exact tests. Chi square tests were used if
there were several categories such as aetiology of renal
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Fig. 1 Examples of LGEpos patterns and quantification methods. a & b A mid-ventricular LGE image with inferior and superior RVIP LGE (a).
Endocardial and epicardial contours are drawn using cvi42 (b) and the maximum area of hyper enhancement selected. Areas of LGE are quantified
using full-width-half maximum methodology and appear pixelated. LGE is given as grams and represented as percentage of total left ventricular mass.
This patient had membranous nephropathy, stage 2 CKD and was in remission at the time of CMR. c & d Mid-wall LGE; Horizontal long axis 4-chamber
view (c) and corresponding mid short axis view (d) showing extensive septal and lateral mid wall LGE in a patient with CKD secondary to Adult
Polycystic Kidney Disease. The patient initially underwent a CMR as part of a research study and was asymptomatic. Coronary angiogram was normal.
Ambulatory ECG monitoring demonstrated sinus rhythm with no arrhythmias. He later had a successful renal transplant with no arrhythmias or
deterioration in LV function. Follow up CMRs have confirmed fixed appearances of LGE. e & f Sub-endocardial; Vertical long axis 2-chamber (e) and
corresponding short axis view (f) demonstrating focal inferior sub-endocardial infarction.* The patient had focal segmental glomerular sclerosis with
stable CKD stage 3 disease. The patient was asymptomatic. He underwent a CT coronary angiogram and calcium score which demonstrated moderate
coronary calcification above the 90th centile for age and gender but no evidence of coronary artery stenosis. g & h Sub-epicardial LGE; Horizontal long
axis 4-chamber view (g) and corresponding basal short axis view (h) with sub-epicardial LGE in the basal-mid inferior wall. The patient was a 59 year
old with Adult Polycystic Kidney Disease and stable CKD stage 3a. He was asymptomatic. There has been no clinical history suggestive of either
sarcoidosis or myocarditis. * Images e & f were originally published in QJM: An International Journal of Medicine [15]
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disease. Kaplan Meier survival curves with Breslow and
Log rank analysis were used to compare survival be-
tween those with and without LGE. Binary logistic re-
gression was used to determine the influence of each
variable on the presence of LGE. The results of the uni-
variate analysis were displayed graphically as a forest
plot. Forward regression was subsequently used for
multivariate analysis. Absolute mean bias and interclass
correlation coefficients were used to determine intra and
inter observer variability.
Results
In total 159 patients underwent LGE-CMR with LGEpos
present in 55 /159 subjects (34%). None of the 43
healthy controls had evidence of LGE [9]. Patient char-
acteristics are presented in Table 1. There were no dif-
ferences in demographics or blood pressure. Median
follow up was 3.8 years [1.04–11.59].
CMR data
Data are presented in Table 2. There were no differences
in RV or LV volumes, function or mass between LGEpos
and LGEneg subjects.
Patterns and quantification of LGE
Patterns of LGE were RVIP n = 28/55 (50.9%), mid wall
n = 18/55 (32.7%), sub-endocardial n = 5/55 (9.1%) and
sub-epicardial n = 4 (7.3%). Examples of these patterns
are presented in Fig. 1. There were no differences in
demographic data, eGFR, blood pressure, ventricular
function or mass between LGEpos and LGEneg subjects
(Tables 1 and 2) or between the different patterns of
LGE in positive patients (see Additional file 1: Table S2).
Sub-group analysis of LGEpos with exclusion of RVIP
patterns (n = 27), demonstrated higher LV mass 69 g/m2
vs 63 g/m2 p = 0.029 and lower LVEF compared with
LGEneg (69% vs. 66% p = 0.05). No specific pattern of
LGE was associated with a defined aetiology. On multi-
variate modelling including demographics, CMR param-
eters and electrocardiogram (ECG) changes as variables,
it was not possible to identify independent predictors of
LGE (see Fig. 2).
The diffuse and RVIP patterns of LGE limited quantifi-
cation (38/55 patients) but accounted for a very small
percentage of overall mass, 1.25 [0.67–2.02] %. Intra-
observer variability (of 10 patients) gave an absolute
mean bias of 0.46% ± 0.43%, interclass correlation coeffi-
cient 0.98 (95% confidence interval 0.91–0.99). Inter-
observer variability (of 10 patients) gave an absolute
mean bias of 0.46 ± 0.80%, interclass correlation coeffi-
cient 0.97 (95% confidence interval 0.90–0.99).
Eight subjects with LGEpos had abnormal ECGs (in
the absence of known CVD) with varied renal aetiology.
Three patients had pathological Q waves; two had RVIP
LGE with inferior Q-waves and one subject had sub-
endocardial LGE pattern corresponding to anterior Q-
waves. Five patients had T wave inversion; three had
RVIP LGE, one had mid wall and one had a sub-
endocardial pattern.
Outcome measures
There were 15/159 patient deaths over follow up (9%);
n = 6 (10.9%) in LGEpos patients and n = 9 (8.5%) in
LGEneg. The cause of death was ascertained in 10 pa-
tients; 6 deaths were due to advanced carcinoma, one
patient died of pneumonia, one patient died of acute car-
diac failure secondary to ischaemic and hypertensive car-
diac disease, one patient died of myocardial infarction
and one patient died of a brain stem haemorrhage sec-
ondary to hypertension. A Kaplan Meier curve for all-
cause mortality did not demonstrate a significant differ-
ence in mortality between the two groups (see Fig. 3).
Cardiovascular morbidity was also low in this cohort
(7%) with no difference between LGEpos and LGEneg;
cardiac events (including heart failure) n = 5 vs. n = 2,
stroke n = 1 vs. n = 2 and peripheral vascular disease n =
1 vs. n = 1. Hospital admissions occurred in 51 subjects
(32%) although 26 of these were renal related admissions
and only 4 subjects were admitted with cardiac causes
(all those with chest pain were admitted for investiga-
tions and subsequent angiograms). The remaining ad-
missions were non-cardiac and included admissions for
a range of medical and surgical complaints including sei-
zures, urinary tract infections, hernias and fractures.
Subgroup analysis
Further analysis was conducted to compare subgroups
of LGE in an attempt to determine whether those with
RVIP patterns had a different risk profile in CKD to
other patterns of LGE. When comparing the patients
with LGEneg or RVIP LGE (n = 132) to all other
remaining patterns of LGE (n = 27) there was no signifi-
cant difference in survival (Log rank p = 0.316, Breslow
p = 0.397). There was also no difference in cardiac
events, heart failure, stroke or peripheral vascular dis-
ease. Similarly when those with RVIP (n = 28) were com-
pared to all other types of LGE (n = 27) there was no
difference in survival (Log rank p = 0.404, Breslow p =
0.299) cardiac events, heart failure, stroke or peripheral
vascular disease.
Discussion
This large retrospective CMR study has examined the
prevalence, patterns and clinical significance of LGE in
patients with pre-dialysis CKD. Over a third of subjects
had evidence of LGE with normal LVEF and low rates of
LVH. However, LGE, did not predict adverse cardiac
events and did not offer incremental risk stratification in
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this population. This finding may reflect that over half of
the LGE was focal at the right ventricular insertion
points, a pattern shown to be associated with a better
prognosis and correlated on histology with myocardial
disarray, increased collagen and fat between fibre bun-
dles but not replacement fibrosis [17]. Only 18/159
(11%) patients had a mid-wall / diffuse pattern in keep-
ing with myocardial interstitial fibrosis from a non-
coronary aetiology which is far lower than the reported
~ 30% seen in non-ischaemic dilated cardiomyopathy
(NI-DCM) where LGE has prognostic stratification [18].
CMR plays an increasingly important role in
characterizing heart disease in CKD and an appreciation
of the myocardial changes frequently present are import-
ant for clinicians. The observed low cardiac event rate
over intermediate follow up might also offer a degree of
reassurance to clinicians when assessing CKD patients
without high risk CV markers such as diabetes or
proteinuria.
RVIP-LGE has been reported not only in NI-DCM, pul-
monary hypertension and hypertrophic cardiomyopathy
but also in athletes [19–21]. It is thought to represent
plexiform fibrosis related to interdigitation of RV and LV
fibers as these form the septum rather than myocardial
Table 1 Baseline patient characteristics according to presence or absence of late gadolinium enhancement on cardiac MRI
LGEpos n = 55 LGEneg n = 104 P value
Age (years) 57 ± 12 53 ± 13 0.069
Male sex n (%) 38 (69) 59 (57) 0.171
BMI 28 ± 4 27 ± 4 0.088
eGFR (ml/min/1.73m2) 54 ± 15 52 ± 16 0.502
KDIGO stage n (%) 0.649
2 (eGFR 60–89 ml/min/1.73m2) 22 (40) 32 (31)
3a (eGFR 45–59 ml/min/1.73m2) 17 (30) 35 (33)
3b (eGFR 30–44 ml/min/1.73m2) 14 (26) 29 (28)
4 (eGFR 15–29 ml/min/1.73m2) 2 (4) 8 (8)
Aetiology n (%) 0.117
Vasculitis 7 (13) 9 (9)
GN 15 (27) 49 (47)
Hereditary 10 (18) 13 (12)
Systemic 8 (14) 9 (8)
Infective 2 (4) 4 (4)
Obstruction 4 (7) 3 (3)
Hypertensive 1 (2) 5 (5)
Interstitial 0 (0) 6 (6)
Vascular 1 (2) 1 (1)
Unknown 7 (13) 5 (5)
Systolic BP (mmHg) 128 ± 17 126 ± 14 0.431
Diastolic BP (mmHg) 78 ± 11 77 ± 10 0.710
Haemoglobin (g/L) 138 ± 14 132 ± 22 0.057
Total cholesterol (mg/dL) 90 ± 18 90 ± 18 0.575
NTproBNP (pg/mL) 55 [34–93] 59 [17–161] 0.656
Immunosuppression usage n (%) 16 (29) 22 (21) 0.326
Anti-hypertensive usage n (%) 45 (82) 83 (80) 0.822
Statin usage n (%) 24 (46) 39 (37) 0.388
ECG n (%)
Q waves 3 (5) 4 (4) 0.931
T inversion 5 (9) 12 (11) 0.789
Continuous variables are presented as mean ± SD if normally distributed or medians and [25th–75th percentile] for skewed variables. Categorical variables are
presented as n (valid %). Significant p values are bold
BMI Body mass index, BP blood pressure, eGFR estimated glomerular filtration rate. GN Glomerulonephritis. KDIGO Kidney Disease Improving Global Outcomes.
LGEpos Patients with late gadolinium enhancement. LGEneg Patients without late gadolinium enhancement
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fibrosis and represents only 1–3% of overall LV mass [22].
The natural history of RVIP-LGE in CKD remains un-
known. Our finding of isolated RVIP-LGE and a more be-
nign phenotype is supported in a recent prospective
observational study examining patterns of LGE in NI-
DCM with severe LV impairment and a mean LVEF of
25% over 46months follow up. RVIP-LGE was present in
14% of the cohort and was associated with higher systolic
and diastolic blood pressure but did not increase the risk
of adverse cardiac event or arrhythmic events compared
to patients with no LGE. Furthermore, there was a lower
incidence of heart failure than observed with myocardial
LGE [17]. In pulmonary hypertension, observational stud-
ies have also shown that RVIP-LGE does not predict mor-
tality in contrast to more extensive LGE extending into
the interventricular septum [21].
In contrast, there are extensive data to support the
role of myocardial LGE as a marker of risk in ischaemic
and non-ischaemic cardiomyopathies even when the
LVEF is normal [1, 18]. Myocardial LGE correlates on
histology with expansion of the extracellular space, in-
creased collage deposition and ultimately irreversible fi-
brosis [23]. The latter serves as a substrate for
ventricular arrhythmias and promotes adverse
Table 2 Cardiac MRI data according to presence or absence of
late gadolinium enhancement
LGEpos n = 55 LGEneg n = 104 P value
LVEDVI (ml/m2) 61 ± 12 59 ± 12 0.484
LVESVI (ml/m2) 19 ± 8 18 ± 7 0.336
LVSV (ml) 82 ± 16 77 ± 17 0.095
LVEF (%) 68 ± 10 70 ± 8 0.382
LVMI (g/m2) 66 ± 14 62 ± 14 0.193
RVEDVI (ml/m2) 67 ± 14 68 ± 13 0.690
RVESVI (ml/m2) 28 ± 11 31 ± 10 0.057
RVSV (ml) 78 ± 17 74 ± 16 0.219
RVEF (%) 62 ± 9 61 ± 7 0.405
LVH 4 (7.3) 4 (3.8) 0.449
Continuous variables are presented as mean ± SD if normally distributed or
medians [25-75th percentile] for skewed variables. Categorical variables are
presented as n (valid %). Significant p values are bold
LVEDVI Left ventricular end-diastolic volume index. LVESVI Left ventricular end
systolic volume index. LVSV Left ventricular stroke volume. LVEF Left
ventricular ejection fraction. LVMI Left ventricular mass index. LVH Left
ventricular hypertrophy. RVEDVI Right ventricular end diastolic volume index.
RVESVI Right ventricular end systolic volume index. RVSV Right ventricular
systolic volume. RVEF Right ventricular ejection fraction
Fig. 2 Predictors of LGE in CKD. Forest plot demonstrating the odds ratio (diamond marker) and 95% confidence intervals of all the factors which
may influence the presence of late gadolinium enhancement on univariate analysis. The odds ratio (OR) is defined per 10 unit change. I.e. for age,
OR given for per 10 years. Binary logistic regression was used for analysis with the dependent variable as the presence of LGE. All p values were
more than 0.05 indicating there was no significant factor which predicts the presence of LGE on CMR. eGFR: Estimated glomerular filtration rate.
LVEDVI: Left ventricular end diastolic volume, indexed. LVESVI: Left ventricular systolic volume, indexed. LVEF: Left ventricular ejection fraction.
LVMI: Left ventricular mass index. LVH: left ventricular hypertrophy. QTc: Corrected QT interval
Price et al. BMC Cardiovascular Disorders          (2019) 19:295 Page 6 of 10
ventricular remodelling [23]. In CKD, histological data
showing myocardial interstitial fibrosis and disarray on
endomyocardial biopsy was first reported in the 1990s
and the subsequent use of LGE-CMR demonstrated 14%
of patients with ESKD had evidence of mid-wall repara-
tive fibrosis [7, 8]. Unlike other disease cohorts, large
outcome studies demonstrating the prognostic role of
LGE in CKD have not followed and further gadolinium
LGE-CMR studies have been restricted since 2006 with
regulatory changes to reflect the reported association be-
tween gadolinium-based contrast agents used for mag-
netic resonance imaging (MRI) procedures and
nephrogenic systemic fibrosis (NSF).
The largest study to date in CKD was a retrospective
analysis of 966 “all comers” undergoing LGE-CMR be-
tween 2006 and 2008 with a serum creatinine measured
within 30 days of CMR. Patients were stratified accord-
ing to eGFR greater or less than 70 ml/min/1.73m2 [24].
The authors demonstrated lower eGFR to be associated
with more LGE even after adjustment for demographics,
coronary disease and diabetes. Stratification of survival
based on eGFR demonstrated higher mortality with
LGEpos and eGFR< 70ml/min1.73m2 with a hazard ra-
tio of 1.8 (1.07–3.04, p = 0.03) compared to LGEneg
subjects [24]. This cohort was a very different population
to our study. Firstly, subjects were ‘all comers’ who had
all undergone CMR for clinical reasons and most sub-
jects had coronary artery disease (54%) or diabetes (16%)
[24]. This contrasts with those recruited to our study,
the majority of whom were identified a priori based on
the presence of renal disease confirmed on biopsy/im-
aging and without cardiovascular disease. Secondly, the
predominant pattern of LGE found in 88% was sub-
endocardial ‘coronary’ infarct, suggesting that the study
by Dandamudi et al. was of a cohort of clinical patients
with ischaemic heart disease and mild secondary renal
impairment (mean eGFR 73ml/min/1.73m2) [24]. The
ratio of sub-endocardial LGE in their study is dispropor-
tionate not only to the amount of a non-coronary pat-
tern seen in our study but also that in the landmark
study by Mark et al. [7].
There are several potential reasons why LGE did not
predict adverse outcomes in our study of CKD contrary
to the near universal finding in non-ischaemic cardiomy-
opathies where “LGE is bad”. Firstly, our cohort was se-
lected as part of research trials to investigate the impact
of CKD on changes in myocardial structure and func-
tion, and hence specifically excluded subjects with
Fig. 3 Kaplan- Meier curve of survival comparisons. A Kaplan-Meier curve demonstrates that there were very few events within those with and
without LGE. There was no significant difference in survival between the two groups (Log Rank Mantel Cox and Breslow tests were non-
significant at p = 0.154 and p = 0.209 respectively)
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diagnosed cardiovascular disease and diabetes. Secondly,
although the majority of our cohort were male, hyper-
tensive and many were prescribed lipid lowering therapy,
most also had only early stage CKD and the overall CV
adverse event rate was low. It is possible that the follow-
up period was too short to identify adverse outcomes re-
lated to myocardial LGE but it may also be that the im-
pact of myocardial fibrosis in CKD may be most adverse
in those with an incremental number of risks, perhaps
including sub-clinical ischaemia. The latter hypothesis is
consistent with the recent scientific statement from the
American Heart Association, concluding that multiple
mechanisms contribute to the progression of uremic car-
diomyopathy rather than this being driven solely by a
decline in eGFR [25]. The impact of multiplicative CV
risk factors including hypertension, calcium-phosphate
metabolism and diabetes on LGE prevalence remains to
be established in higher risk CKD cohorts.
Limitations and clinical implications
There are several limitations of our study; the data were
retrospectively acquired and are observational from pre-
defined and selected research cohorts. The small sample
size, long follow up and small number of events makes
this study vulnerable to type two statistical error. The
low number of adverse clinical outcomes is partly due to
a highly selected patient group and single centre data
which might have precluded identification of an inde-
pendent association of adverse events with LGE. It is
also possible that clinical events have been missed in pa-
tients presenting to other hospitals. We acknowledge a
selection bias in our cohort. Patients recruited into our
studies are a highly selected group with controlled blood
pressure and without diabetes and many comorbidities.
The aetiology is also most commonly primary glomer-
ulonephritis or adult polycystic kidney disease. We also
acknowledge that the duration of CKD would be ex-
pected to affect the prevalence of myocardial disease.
However, it was not possible to reliably established this
vintage in pre-dialysis patients many of whom were only
referred from primary care at a stage of more rapid de-
cline or falling below eGFR referral cut offs. Further
studies will require the enrolment of unselected subjects
with CKD and longer follow up times to assess the prog-
nostic implications of LGE in CKD. It is noteworthy that
we have no reported cases of NSF in over 10 years of
CKD based research. However, precautions are taken to
minimise dose (0.15–0.2 mmol/kg), newer low risk gado-
linium agents are used (Gadovist®) and contrast is
avoided in patients with acute kidney injury and when
eGFR < 30ml/min/1.73m2. The absence of any cases of
NSF is reassuring but, our sample size is too small and
NSF is too rare to draw conclusions.
Recruitment and data collection commenced before
widespread availability of newer non-contrast T1 map-
ping CMR sequences. These sequences have undoubt-
edly allowed better detection of diffuse fibrosis which
can be “missed” with LGE inversion recovery sequences
due to limited spatial resolution [26]. Observational data
in CKD cohorts have been consistent in demonstrating
elevated native T1 times in early stage CKD and ESKD
on dialysis [9, 27, 28]. However, to date there is not
histological correlation with T1 in CKD. Indeed a recent
proof of concept study correlating the extent of myocar-
dial fibrosis on LGE with absolute native T1 signal failed
to identify “cut off” thresholds in a validation model
[29]. To date, the most comprehensive assessment of
myocardial fibrosis and its clinical impact appears to be
through combining multi-parametric CMR biomarkers
of LGE, T1 and ECV. This approach was recently used
in a cohort with aortic stenosis and successfully identi-
fied patients with worse LV remodelling, adverse blood
biomarkers such as NT pro-BNP and worse functional
capacity [30]. Continued restrictions on use of gadolin-
ium in CKD means T1 mapping endpoints will poten-
tially have increasing importance for longitudinal follow
up and outcome prediction.
Conclusions
LGE is common in patients with pre-dialysis CKD who
do not have clinical ischaemic heart disease. The pre-
dominant pattern was in the RVIP distribution with
lower rates of mid-wall fibrosis than is reported in non-
ischaemic cardiomyopathy. In this low risk, stable co-
hort, rates of CV events were low and LGE did not pre-
dict an adverse prognosis. This study does not exclude
an association between mid-wall/myocardial LGE and
adverse prognosis in those with advanced CKD and mul-
tiple risk factors.
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